Disorder of urinary system
Methodology & AI Transparency ⓘ
Disorder of urinary system Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Prostate (BPH), Bladder & Urinary Tract diagnostic criteria (N39.9), workup for Disorder of urinary system integrates IPSS symptom scoring [Disorder of urinary system N39.9] with evidence-graded therapy tailored to Total PSA & in Disorder of urinary system (N39.9: Serum Creatinine/eGFR) response.
- 2 Real-world patient consensus: Mapped to Prostate (BPH), Bladder & Urinary Tract under ICD-10-CM N39.9 for Disorder of urinary system clinical workups.
- 3 Typical cash cost range: Primary evaluation for Disorder of urinary system incorporates IPSS symptom scoring [Disorder of urinary system N39.9] and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Disorder of urinary system: Total PSA & in Disorder of urinary system (N39.9: Serum Creatinine/eGFR) (Age-specific PSA; eGFR > 75 mL/min (N39.9)) and IPSS Urinary Symptom in Disorder of urinary system (N39.9: Score).
Ask our AI Specialists anything about Disorder of urinary system
What Is Disorder of urinary system?
Under Prostate (BPH), Bladder & Urinary Tract diagnostic criteria (N39.9), workup for Disorder of urinary system integrates IPSS symptom scoring [Disorder of urinary system N39.9] with evidence-graded therapy tailored to Total PSA & in Disorder of urinary system (N39.9: Serum Creatinine/eGFR) response.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in urology & prostate, Disorder of urinary system (N39.9) involves alpha-1A adrenergic smooth-muscle in Disorder of urinary system (N39.9: tone narrowing the). progression correlates with shifts in Total PSA & in Disorder of urinary system (N39.9: Serum Creatinine/eGFR) (Age-specific PSA; eGFR > 75 mL/min (N39.9)).
Common Symptoms & Clinical Signs
- • Presentation of Disorder of urinary system (N39.9): burning dysuria, suprapubic in Disorder of urinary system (N39.9: discomfort, or cloudy/hematuric)
- • Secondary Disorder of urinary system clinical sign: sudden severe flank-to-groin in Disorder of urinary system (N39.9: colicky pain caused)
- • Symptom flares in Disorder of urinary system correlating with Total PSA & in Disorder of urinary system (N39.9: Serum Creatinine/eGFR) deviation outside Age-specific PSA; eGFR > 75 mL/min (N39.9)
- • Functional urology & prostate impact requiring IPSS symptom scoring [Disorder of urinary system N39.9] evaluation (N39.9)
Disorder of urinary system Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N39.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Prostate (BPH), Bladder & Urinary Tract | NLM Clinical Tables |
| Diagnostic / Lab Marker: Total PSA & in Disorder of urinary system (N39.9: Serum Creatinine/eGFR) | Age-specific PSA; eGFR > 75 mL/min (N39.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: IPSS Urinary Symptom in Disorder of urinary system (N39.9: Score) | 0 – 7 (mild symptoms) (N39.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urinalysis & Post-Void in Disorder of urinary system (N39.9: Residual (PVR)) | Negative leukocyte/nitrite; PVR < 50 mL (N39.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Disorder of urinary system
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Cyclopentolate Hydrochloride Cyclogyl • RxCUI 1298066 | Eye Health Agent | 78% | $0.8507 | $ 7.60 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Disorder of urinary system)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake: What a 10,039-Participant Study Found Higher doses of SSRIs appear slightly more effective in depression. The American journal of psychiatry • 2016-02-01 • Meta-Analysis | N = 10,039 | 99/100 | PMID 26552940 ↗ |
| New Insights on Pharmacological and non-pharmacological treatments for depression in: What a 10,991-Participant Study Found Herbal medicine and mirtazapine had no significant difference in overall risk of side effects compared with placebo. Psychiatry research • 2019-11-15 • Meta-Analysis | N = 10,991 | 99/100 | PMID 31627074 ↗ |
| New Insights on Antidepressants for the treatment of adults with depression in the maintenance: What a 9,384-Participant Study Found Compared to placebo, venlafaxine was associated with a lower incidence of dizziness, while desvenlafaxine, sertraline, and vortioxetine were associated with a higher incidence of nausea/vomiting. Molecular psychiatry • 2023-01-15 • Meta-Analysis | N = 9,384 | 99/100 | PMID 36253442 ↗ |
| New Insights on Modeling the efficacy of a novel antidepressant zuranolone for: What a 8,735-Participant Study Found Primary side effects related to zuranolone included somnolence, headache, dizziness, and sedation, with no severe safety signals observed. Journal of affective disorders • 2026-01-01 • Meta-Analysis | N = 8,735 | 99/100 | PMID 40876640 ↗ |
| New Insights on Comparative efficacy and acceptability of anxiolytic drugs for the treatment of: What a 28,637-Participant Study Found This network meta-analysis provides a unique comparison of the efficacy and acceptability of anxiolytics. European archives of psychiatry and clinical neuroscience • 2026-06-15 • Meta-Analysis | N = 28,637 | 99/100 | PMID 40788541 ↗ |
Disorder of urinary system Patient Community & “People Like Me” Threads
Filter Disorder of urinary system community threads and patient logs by age, biological sex, dosage, and treatment duration.